{
    "nctId": "NCT00674011",
    "briefTitle": "Hypertension in Breast Cancer Patients Receiving Bevacizumab",
    "officialTitle": "A Pilot Study of Hypertension in Breast Cancer Patients Receiving Bevacizumab",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "To evaluate changes in flow-mediated vasodilation (FMD) from baseline to treatment timepoints in an effort to explore the relationships between exposure to bevacizumab, eNOS activity, and vascular dysfunction.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer\n* Must be starting combination treatment with bevacizumab and chemotherapy. Treatment may not have already started. Patients may receive therapy either on or off of a clinical trial.\n* Any number of prior chemotherapy or biological therapy regimens is acceptable.\n* Either no history of hypertension, defined as Blood Pressure \\<140/90mm Hg on no antihypertensive therapy, or medically controlled pre-existing hypertension, defined as Blood Pressure \\< 140/90mm HG on one non-angiotensin converting enzyme inhibitor (ACE-I) or non-angiotensin receptor blocking (ARB) medication.\n\nExclusion Criteria:\n\n* History of uncontrolled hypertension within the previous 6 months\n* Inability to assess blood pressure or have prolonged blood pressure cuff inflation due to history of bilateral lymph node dissections, presence of an indwelling venous access device, or other condition\n* Concurrent use of a statin medication\n* Systolic blood pressure \\< 100mm Hg",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}